Real-world safety assessment of MET-targeted therapies: a pharmacovigilance analysis using the FAERS database
Background Globally, lung cancer is the foremost contributor to cancer-associated fatalities. Of its various histological sub-types, non-small-cell lung cancer (NSCLC) constitutes the vast majority, accounting for more than 85% of diagnoses. A key driver in this pathology is the mesenchymal–epithelial transition (MET)...